Nasdaq

Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment

Phase 2a trial results show laromestrocel (Lomecel-B™) improves cognitive function and brain volume in mild Alzheimer's disease patients. Longeveron Inc. announced positive results from its Phase 2a ...
Monthly Prescribing Reference

Lomecel-B Granted Fast Track Status for Hypoplastic Left Heart Syndrome

Lomecel-B is delivered via intramyocardial injection. The Food and Drug Administration (FDA) has granted Fast Track designation to Lomecel-B ™, an investigational allogeneic, bone marrow-derived ...
Yahoo Finance

Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference ...

Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron · GlobeNewswire Inc. MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage ...
Benzinga.com

Why Is Alzheimer's-Focused Longeveron Stock Trading Higher On Monday?

On Sunday, Longeveron Inc (NASDAQ:LGVN) presented Phase 2a clinical trial data and biomarker results at the Alzheimer’s Association International Conference (AAIC). The Phase 2a CLEAR MIND trial ...
Nasdaq

Longeveron Inc. Announces International Non-proprietary Name Approval for Lomecel-B™ as "Laromestrocel"

Lomecel-B™ is now known as laromestrocel, a cellular therapy for Alzheimer's and hypoplastic left heart syndrome, following WHO approval. Longeveron Inc. has announced that its cellular therapy ...
Business Insider

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual ...

MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ...
Benzinga.com

Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Longeveron Inc. (NASDAQ: LGVN) is optimistic ...
manilatimes

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

MIAMI, March 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ...
Monthly Prescribing Reference

Lomecel-B Granted Orphan Drug Status for Hypoplastic Left Heart Syndrome

Credit: Getty Images. Lomecel-B is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy adult donors. The Food and Drug Administration (FDA) has ...
Yahoo Finance

Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

Wa'el Hashad, CEO, Longeveron · GlobeNewswire Inc. MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, ...
Business Insider

Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference ...

Findings offer potential mechanistic and clinical insights in the development of cellular therapy Lomecel-B™ for mild Alzheimer’s disease (AD) Lomecel-B™ capacity to inhibit MMP14 correlates with ...